## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Confirmation No.: Unassigned

10/635,808

Application No.: Applicant:

Rapin, et al. August 5, 2003

Filed: TC/A.AU.: Unassigned Unassigned

Examiner:

NEURO 103

Docket No.:

Customer No .:

Tripeptide Derivatives for the Treatment of

Title:

Postlesional Diseases of the Nervous System

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

The citation of information on the attached Form PTO-1449, "List of Art Cited by

Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each reference is enclosed. The Examiner's attention is drawn to the following co-pending applications: U.S.S.N. 10/635,696; Sir:

U.S.S.N. 10/635,797; and U.S.S.N. 10/635,805.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable

This Information Disclosure Statement is filed before receipt of a first Office action on statutes, Rules of Practice in patent cases, or otherwise.

the merits of this application, thus no fee payment as set forth under § 1.17(p) is enclosed. If any other fee is due, please charge any fees or credit any overpayment to Deposit Account No. 11-0980.

Madely

Madeline I Johnston Reg. No. 36,174

191 Peachtree Street, N.E., Atlanta, GA 30303 King & Spalding, LLP

Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents PO Rox 1450 Alexandria VA 22313-1450 on November 25 2003. I hereby certify that this correspondence is being deposited with the United States Postal Service as first class me thereby certify that this correspondence is being deposited with the United States Postal Service as first class me addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 25, 2003.

3342799\_6

Sheet

of

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**NEURO 103** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 10/635,808 INFORMATION DISCLOSURE **Filing Date** August 5, 2003 STATEMENT BY APPLICANT First Named Inventor Rapin, et al. Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned

Attorney Docket Number

3354595\_1

U.S. PATENT DOCUMENTS								
Examiner Initials *	Number Kind Codel		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	AA	5,212,158	A	VANDAI	05-18-1993			
-	AB	5,973,111	A	BEMIS, et al.	10-26-1999			
	AC	6,156,572	A	BELLAMKONDA, et al.	12-05-2000			
	AD	6,235,929	B1	POWERS	05-22-2001			

3

			F	OREIGN	PATENT DOCUMENTS	3		
Examiner Initials *	Cite No. 1	Office <sup>3</sup>		ent ind Code <sup>2</sup> if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	AE	EP	0,316,218	A1	INORGAN, S.A.	05-17-1989		
	AF	EP	1,018,341	Α	CALPIS Co., Ltd.	07-12-2000		
	AG	EP	1,231,279	A1	CALPIS Co., Ltd.	08-14-2002		
	AH	EP	0,446,706	A2, A3	MERCK PATENT GESELLSCHAFT	09-18-1991		
	AI	JР	04-005240 w/ PAJ abstract	A	TAISHO PHARMACEUT. Co.;	01-09-1992		
	AJ	wo	88/09604	A2	MEDICIS Corp.	12-15-1988		
	AK	wo	92/11850	A2	CORTEX PHARMA; GA. TECH. RES. INST.	07-23-1992		
	AL	wo	96/41638	A1	SANOFI WINTHROP	12-27-1996		
	AM	WO	98/14202	A1	AUCKLAND UNISERVICES, Ltd.	04-09-1998		
	AN	WO	01/28578	A2, A3	WRAIR	04-26-2001		
	AO	WO	01/34828	A1	CALPIS Co. Ltd.	05-17-2001		T
	AP	WO	01/68114	A1	MONSANTO Co. (US)	09-20-2001		T
	AQ	WO	02/062373	A2,A3	TELL PHARM. AG	08-15-2002		
	AR	WO	02/062828	A2,A3	TELL PHARM. AG	08-15-2002		T

Examiner Signature	Date Con:	sidered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449A/PTO			Complete if Known		
Cabonic				Application Number	10/635,808	
	ORMATION D			Filing Date	August 5, 2003	
STA	TEMENT BY	APPLI	CANT	First Named Inventor	Rapin, et al.	
				Group Art Unit	Unassigned	
	(use as many sheets	as neces	sary)	Examiner Name	Unassigned	
Sheet	2	of	3	Attorney Docket Number	NEURO 103	

3354595\_1

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup> .
	BA	BEYER, H., and WALTER, W., Handbook of Organic Chemistry, by S. Hirzel Verlag, Stuttgard (English translation of the 22 <sup>nd</sup> edition of Lehrbuch der Organischen Chemie) (1996), pp. 827-838.	
	BB	BLUNDELL, T.L., et al., "Knowledge-based protein modelling and design", Eur. J. Biochem., 172:513-520 (1988).	
	ВС	CHESSEBEUF, M., et al., "Rat liver epithelial cell cultures in a serum-free medium: primary cultures and derived cell lines expressing differentiated functions", In Vitro, 20(10):780-795 (1984).	
	BD	CLARK, M.C., et al., "Validation of the general purpose Tripos 5.2 force field", J. Comp. Chem., 10(8):982-1012 (1999).	
	BE	DE POOTER, H., et al., "N-acylamino acids and peptides IV the synthesis of N-cinnamyl-, N-p.coumaryl- and N-caffeyl-glycine and -glycyl-L-phenylalanine", Bull. Soc. Chim. Belg., 85(9):647-656 (1976). XP008015013.	
	BF	FADEN, A.I., et al., "Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents", Amer. J. Physiology 277(4, pt. 2):R1196-R1204 (1999), Chem. Abstr. 132:31033 XP002207513, XP008014976.	
	BG	FADEN, A.I., et al., "Structure-activity relationships of TRH analogs in rat spinal cord injury", Brain Research, 448:287-293 (1988). XP008015202.	
	ВН	GASTEIGER, J., et al., "Iterative partial equalization of orbital electronegativity a rapid access to atomic charges", <i>Tetrahedron</i> , 36:3219-3238 (1980).	
· · · · ·	BI	HAGG, T., et al., "Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage", Exp. Neurol., 101:303-312 (1988).	
	BJ	JONES, D.T., et al., "A new approach to protein fold recognition", Nature, 358:86-89 (July 1992).	
	BK	JONES, D.T., "Protein secondary structure prediction based on position-specific scoring matrices", J. Mol. Biol., 292(2):195-202 (1999).	
	BL	KANSY, M., et al. "Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes", J. Med. Chem., 41(7):1007-1010 (March 26, 1998).	
	BM	KHUEBACHOVA, M., et al., "Mapping the C terminal epitope of the Alzheimer's disease specific antibody MN423", J. Immunol. Methods (Elsevier Amsterdam, NL) 262(1-2):205-215 (2002). XP004352190.	

Examiner Signature		Date Considered	_

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute f	or form 1449A/PTO			Complete if Known		
Cubolituto I	0.10			Application Number	10/635,808	
	RMATION D			Filing Date	August 5, 2003	
STAT	EMENT BY	APPLI	CANT	First Named Inventor	Rapin, et al.	
				Group Art Unit	Unassigned	
ļ	(use as many sheets	s as neces	sary)	Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number	NEURO 103	

3354595\_1

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	CA	LASKOWSKI, R.A., et al., "PROCHECK: a program to check the stereochemical quality of protein structures", J. Appl. Cryst., 26:283-291 (1993).	
	СВ	LE PONCIN-LAFITTE, M., et al., "Sound-avoidance conditioning and a mathematical approach to the description of acquisition performance", Math. Biosciences, 59:249-268 (1982).	
	CC	LUCO, J.M., "Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling", J. Chem. Inf. Comput. Sci., 39 (2):396-404 (1999)	
	CD	PARNETTI, L., et al., "Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid", Acta Neurol. Scand. 92:135-140 (1995).	
<del></del>	CE	VARON, S., et al., "Nerve Growth Factor in CNS Repair", J. Neurotrama, 11(5) (1994)	
	CF	WANG, R., et al., "SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex", J. Mol. Model., 4:379-394 (1998).	
	CG	WEINER, S.J., et al., "A new force field for molecular mechanical simulation of nucleic acids and proteins", J. Am. Chem. Soc., 106:765-784 (1984)	
	СН	WIESMAN, C., et al., "Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor", Nature, 401:184 (September 9, 1999).	

Examiner Date	
Examiner Date Date	
Signature Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.